Bio-Techne Corporation


Want a discount? Become a member by purchasing Annual Subscription!
SKU: TECH-1 Category:


Bio-Techne Corporation delivered a disappointing set of results as the company was unable to meet Wall Street’s revenue and earnings expectations. However, despite industry-wide challenges, the company achieved a commendable 2% organic growth. Persistent headwinds influenced performance, including a subdued biotech funding environment, inventory destocking from OEM customers, and broader economic issues in China. Although the US biopharma funding challenges and evolving macroeconomic conditions in China exceeded initial expectations, Bio-Techne’s growth pillars, such as the GMP proteins business, ExoDx prostate, and ProteinSimple franchise, demonstrated robust performance. In the Diagnostics and Genomics segment, ExoDx prostate test volume increased by almost 50%, showcasing significant growth potential. The Spatial Biology business, including ACD and Lunaphore, demonstrated upper single-digit organic growth. BaseScope and microRNA Scope reported substantial increases, underlining their importance in gene therapy applications. The integration of Lunaphore into the Spatial Biology business is progressing well, with a positive reception for the COMET instrument, a fully automated platform. Efforts are underway to develop the first fully automated spatial and multi-omic workflow, combining the strengths of Lunaphore’s technology and ACD’s RNAscope HiPlex.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!